Market Intelligence, Clinical Progress, and High-Purity Reagents for Apoptosis-Targeting Cancer Therapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for Survivin drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | BIRC5 (Survivin) Recombinant Protein (WT & ΔEx3 Isoform) High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. Theoretical MW confirmed. |
View BIRC5 Products |
| Gene Delivery | BIRC5 ORF Clone / Lentiviral Particles Full-length ORF for stable cell line construction. CMV promoter, Puromycin selection. |
View BIRC5 Products |
| Benchmark Ab | Anti-BIRC5 Biosimilar / Control Recombinant positive control for western blot and IHC. |
View BIRC5 Products |
| Validator | BIRC5 siRNA Set (3 unique sequences) For knockdown verification and specificity controls. |
View BIRC5 Products |
| Partner Protein A | XIAP (BIRC4) Recombinant Protein IAP family counter-screening for selectivity assays. |
View XIAP Products |
| Partner Protein B | DIABLO/Smac Recombinant Protein Pro-apoptotic binding partner for competitive binding assays. |
View DIABLO Products |
| Related Target C | BIRC2 (cIAP1) Recombinant Protein Parallel IAP family member for off-target profiling. |
View BIRC2 Products |
| Related Target D | BCL2 Recombinant Protein Key regulator of intrinsic apoptosis pathway; for combination studies. |
View BCL2 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Homodimerization Interface Targeting (BIR-BIR interaction) | High-purity monomeric BIRC5 protein with confirmed single-band purity (>95%) by SDS-PAGE; ideal for dimerization disruption assays |
| Nuclear vs Cytoplasmic Localization Studies | Lentivirus-GFP fusion constructs for live-cell imaging; HEK293 expressed native folding |
| IAP Family Selectivity (XIAP, cIAP1/2 off-target) | Homolog panel (BIRC2, BIRC3, BIRC4) proteins strictly verified by mass spec; sequence identity cross-check |
| False Positives in Binding Assays | Validated siRNA included for target-specificity confirmation; DIABLO/Smac positive control for competitive displacement |
Live BIRC5 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of Survivin (BIRC5) represents a persistent challenge in oncology drug development. Major players are shifting focus from traditional modalities to PROTACs, mRNA vaccines, and antisense oligonucleotides (ASOs). Following the discontinuation of first-generation antisense oligonucleotides (LY2181308) and small molecule inhibitors (YM155/sepantronium bromide) due to efficacy and toxicity profiles, the field has pivoted toward next-generation modalities. Current R&D focuses on isoform-selective targeting (wild-type vs. ΔEx3), PROTAC-mediated degradation, and combination strategies with immune checkpoint inhibitors. As the understanding of Survivin's dual role in apoptosis inhibition and mitotic regulation deepens, assay systems capable of discriminating between these functional states are becoming critical for candidate selection.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antisense Oligonucleotides | Eli Lilly (Historical), Isis/ Ionis | Solid Tumors (Lung, Lymphoma) | Knockdown validation (Need validated siRNA controls) |
| Small Molecule Inhibitors | Astellas, Novartis, Academic groups | Solid Tumors, Leukemia, Refractory Cancers | Dimerization disruption assay (Need pure monomeric protein) |
| PROTACs/Degraders | Emerging Biotech, Nurix (indirect), Various Biotech | IAP-Addicted Tumors, Refractory Cancers | Ternary complex formation (Need purified ligases and BIRC5) |
| Peptide/Miniproteins | Academic Consortia | Pediatric Cancers, Solid Tumors | Competitive binding (Need Smac/DIABLO partner proteins) |
| Cancer Vaccine / RNAi | CureVac, Moderna | Advanced Solid Tumors | In vitro validation (Need validated siRNA and stable cell lines) |